Peer-reviewed articleOpen access

Fixed dose combination dextromethorphan-bupropion: A hope for treatment resistant depression (TRD).

Das R, Chakravarty R, Gantait VV, Bhattacharjee S

Indian journal of psychiatryJun 11, 2025License: open accessIndia2 citationsDOI: 10.4103/indianjpsychiatry_315_25

Abstract

<h4>Background</h4>Treatment resistant depression (TRD) has been identified as non-response to depression with adequate dose and trial of two antidepressant medications of different classes. Near about 30% depressive patients are TRD cases. Olanzapine-fluoxetine combination, rTMS, Intravenous ketamine and Electroconvulsive therapy have been till now studied in TRD. Dextromethorphan-bupropion is a newer antidepressant, which has been found to be effective, fast-acting, and well tolerated medicine for depression.<h4>Cases and conclusion</h4>We used this novel antidepressant in three cases of TRD, alone and with combination, and it showed satisfactory response within 2 weeks.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

KetamineDepression

Keywords

Treatment Resistant DepressionDextromethorphan-bupropion

View paper Full text (PDF)

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

Related research

ArticleKetamine

Pharmacologic Approaches to Suicide Prevention.

Zisook S, Domingues I, Compton J

Europe PMC2023

ArticleKetamine

Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature.

Drozdz SJ, Goel A, McGarr MW +6

Europe PMC2022

ArticleKetamine

Effects of ketamine on individual symptoms and symptom networks of depression in a randomised controlled trial of ketamine for treatment-resistant depression.

Hossein S, Rengasamy M, Uzamere A +5

Europe PMC2025